Search

everythinglearnresearchcommunity

for

Search:↓

Polycystic Ovary Syndrome (PCOS) is common in women with conditions like anovulation, hirsutism, hair loss, and type 2 diabetes, and it can lead to health risks like heart disease, obesity, insulin resistance, and depression. Non-Classic Congenital Adrenal Hyperplasia (NC-CAH) is also discussed.

Hair follicles convert androgens, affecting hair loss patterns.

Androgenetic alopecia is common hair loss due to genetics and DHT.

CAH is a genetic disorder affecting cortisol production and causing hormonal imbalances, with treatment and diagnosis varying by form and symptoms.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

Two women with very high androgen levels had only slight skin issues, one due to a non-classical adrenal disorder and the other due to an adrenal tumor.

Eurycoma longifolia extract may help increase testosterone levels and reduce andropause symptoms.

Minoxidil may harm male reproductive health by causing testicular damage and hormonal disruption.

Genetic variants in CYP genes may worsen PCOS symptoms.

Short-term diabetes can cause changes in brain steroids, cholesterol balance, and mitochondrial function.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Steroid sulfatase inhibitors could help treat hormone-related disorders and cancers.

Steroid sulfatase inhibitors could potentially treat hormone-related disorders like certain cancers, hair loss, acne, and improve cognitive dysfunction.

Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.

New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.

Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.

Compound 15a was effective in inhibiting 5α-reductase.

New compounds were made that block an enzyme linked to breast cancer better than existing treatments.

Scientists found new, better-working inhibitors for a hormone-related enzyme.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.

Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.

Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.

Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.

Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.

Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.

A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.